Creating a comprehensive and robust oligonucleotide supply chain: aligning raw materials with the final therapeutic

Oligonucleotide manufacturing does not fail at a single point – it fails at the seams between stages. This article examines the integrated supply chain from raw material sourcing through drug substance synthesis (SPOS or enzymatic ligation), purification, bioconjugation, and drug product formation, highlighting how upstream constraints in reagent supply and GMP capacity propagate downstream to affect timelines, technology selection, and commercial launch readiness.

What you will learn

01

How upstream reagent and GMP capacity constraints propagate downstream to delay launch

02

Where fragmented multi-site networks lose time and money at every CDMO handoff

03

How to weigh build, buy, or hybrid models across modality and development stage

Key interests

Oligonucleotide manufacturing Integrated supply chain CDMO strategy Phosphoramidites Enzymatic ligation GalNAc conjugation Fill–finish GMP capacity

Please enter your email to access content Read now